AbbVie (ABBV) Retained Earnings (2012 - 2026)
AbbVie (ABBV) reported Retained Earnings of -$17.9 billion for Q1 2026, down 925.95% year-over-year from $2.2 billion in Q1 2025, and down 1462.24% quarter-over-quarter from -$1.1 billion in Q4 2025.
AbbVie (ABBV) Retained Earnings (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Retained Earnings data on file, last reported at -$17.9 billion in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$17.9 billion, down 925.95% year-over-year; the trailing twelve-month figure through Mar 2026 was -$17.9 billion (down 925.95% YoY), and the FY2025 annual result was -$1.1 billion, up 85.52% from the prior year.
- Retained Earnings retreated to -$17.9 billion in Q1 2026 per ABBV's latest filing, from -$1.1 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $5.1 billion in Q1 2022 and troughed at -$17.9 billion in Q1 2026.
- A 5-year average of -$2.7 billion and a median of -$1.7 billion in 2025 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings surged 213.31% in 2022, then slumped 925.95% in 2026.
- A 5-year view of Retained Earnings shows it stood at $4.8 billion in 2022, then slumped by 120.9% to -$1.0 billion in 2023, then plunged by 690.0% to -$7.9 billion in 2024, then soared by 85.52% to -$1.1 billion in 2025, then slumped by 1462.24% to -$17.9 billion in 2026.
- Business Quant data shows ABBV's Retained Earnings at -$17.9 billion in Q1 2026, -$1.1 billion in Q4 2025, and -$14.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 1.90 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 29.51 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -14.83 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -17.87 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.37 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.87 Bn |
| Dec 31, 2025 | -1.14 Bn |
| Sep 30, 2025 | -14.23 Bn |
| Jun 30, 2025 | -1.54 Bn |
| Mar 31, 2025 | -1.74 Bn |
| Dec 31, 2024 | -7.90 Bn |
| Sep 30, 2024 | -4.96 Bn |
| Jun 30, 2024 | -3.77 Bn |
| Mar 31, 2024 | -2.38 Bn |
| Dec 31, 2023 | -1.00 Bn |
| Sep 30, 2023 | 933.00 Mn |
| Jun 30, 2023 | 1.79 Bn |
| Mar 31, 2023 | -2.23 Bn |
| Dec 31, 2022 | 4.78 Bn |
| Sep 30, 2022 | -3.44 Bn |
| Jun 30, 2022 | 3.52 Bn |
| Mar 31, 2022 | 5.10 Bn |
| Dec 31, 2021 | 3.13 Bn |
| Sep 30, 2021 | -3.16 Bn |
| Jun 30, 2021 | -3.10 Bn |